Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study G. Wang, L. Bi, X. Li, Z. Li, D. Zhao, J. Chen, D. He, C.-N. Wang, H. Dueñas, V. Skljarevski, L. Yue Osteoarthritis and Cartilage Volume 25, Issue 6, Pages 832-838 (June 2017) DOI: 10.1016/j.joca.2016.12.025 Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions
Fig. 1 Patient disposition. Osteoarthritis and Cartilage 2017 25, 832-838DOI: (10.1016/j.joca.2016.12.025) Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions
Fig. 2 Change in mean of 24-h BPI Average Pain severity. Abbreviations: N = number of randomized patients with nonmissing data at week 1 postbaseline. Osteoarthritis and Cartilage 2017 25, 832-838DOI: (10.1016/j.joca.2016.12.025) Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions
Fig. 3 Response to treatment* and proportions of patient responses to treatment on the PGI-Improvement Scale. *Note: Response to treatment was defined as endpoint PGI-Improvement rating of either ‘much better’ or ‘very much better’. aP-value assesses placebo vs duloxetine for response categories overall (a Fisher exact test). Abbreviation: N = Number of randomized patients with nonmissing data at baseline and endpoint. Osteoarthritis and Cartilage 2017 25, 832-838DOI: (10.1016/j.joca.2016.12.025) Copyright © 2017 Osteoarthritis Research Society International Terms and Conditions